Prestige BioPharma Limited (KRX:950210)
South Korea · Delayed Price · Currency is KRW 5,640.00
-320.00 (-5.37%)
Oct 12, 2026, 3:30 PM KST
Prestige BioPharma Income Statement
Financials in millions KRW. Fiscal year is July - June.
Millions KRW. Fiscal year is Jul - Jun.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
| 26,072 | 14,326 | 689.08 | 161.84 | - | |
Revenue Growth | 81.99% | 1978.97% | 325.77% | - | - |
Cost of Revenue | 42,304 | 26,563 | 11,291 | 33.94 | 228.95 |
Gross Profit | -16,232 | -12,237 | -10,602 | 127.9 | -228.95 |
Selling, General & Admin | 19,643 | 23,307 | 19,108 | 58,231 | 54,422 |
Research & Development | 42,512 | 19,123 | 23,414 | - | - |
Amortization of Goodwill & Intangibles | 7,944 | 2,782 | 178.99 | - | - |
Other Operating Expenses | 573.69 | 520.59 | 1,326 | - | - |
Operating Expenses | 77,189 | 54,348 | 51,636 | -906.28 | 122,460 |
Operating Income | -93,422 | -66,585 | -62,238 | 1,034 | -122,689 |
Interest Expense | -6,923 | -7,626 | -7,404 | -950.8 | -18.85 |
Interest & Investment Income | 3,615 | 9,137 | 12,402 | 10,464 | 2,729 |
Earnings From Equity Investments | - | - | - | -16.96 | - |
Currency Exchange Gain (Loss) | -4,391 | 2,145 | -4,232 | -924.24 | -1,592 |
Other Non Operating Income (Expenses) | 6,872 | 7,397 | 6,693 | 4,034 | 2,282 |
EBT Excluding Unusual Items | -94,248 | -55,533 | -54,779 | 13,639 | -119,288 |
Gain (Loss) on Sale of Investments | -277.2 | - | - | - | - |
Gain (Loss) on Sale of Assets | 6.37 | -6.7 | 89.4 | 72.12 | 211.59 |
Asset Writedown | -28,527 | 59,462 | - | -15,807 | -91,573 |
Pretax Income | -123,045 | 3,923 | -54,689 | -2,095 | -210,649 |
Income Tax Expense | -151.6 | -248.48 | 408.68 | 763.28 | 800.66 |
Earnings From Continuing Operations | -122,894 | 4,171 | -55,098 | -2,859 | -211,450 |
Minority Interest in Earnings | 31,395 | 18,126 | 22,177 | 20,428 | - |
Net Income | -91,499 | 22,297 | -32,921 | 17,569 | -211,450 |
Net Income to Common | -91,499 | 22,297 | -32,921 | 17,569 | -211,450 |
Net Income Growth | - | - | - | - | - |
Shares Outstanding (Basic) | 60 | 60 | 60 | 60 | 60 |
Shares Outstanding (Diluted) | 60 | 60 | 60 | 60 | 60 |
Shares Change | - | 0.22% | -0.22% | - | 16.46% |
EPS (Basic) | -1522.54 | 371.02 | -549.00 | 292.35 | -3518.53 |
EPS (Diluted) | -1522.60 | 371.00 | -549.00 | 292.35 | -3796.17 |
EPS Growth | - | - | - | - | - |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Free Cash Flow | -61,790 | -92,877 | -68,091 | -108,636 | -102,336 |
Free Cash Flow Per Share | -1028.19 | -1545.47 | -1135.49 | -1807.71 | -1702.88 |
Gross Margin | -62.26% | -85.42% | - | 79.03% | - |
Operating Margin | -358.33% | -464.80% | -9032.13% | 639.01% | - |
Profit Margin | -350.95% | 155.64% | -4777.60% | 10855.90% | - |
Free Cash Flow Margin | -237.00% | -648.33% | -9881.47% | -67125.45% | - |
EBITDA | -60,665 | -44,785 | -45,971 | 12,684 | -118,822 |
EBITDA Margin | -232.69% | - | - | 7837.31% | - |
D&A For EBITDA | 32,757 | 21,801 | 16,267 | 11,650 | 3,867 |
EBIT | -93,422 | -66,585 | -62,238 | 1,034 | -122,689 |
EBIT Margin | - | - | - | 639.01% | - |
Advertising Expenses | 1,036 | 869.23 | 970.57 | - | - |